Results 61 to 70 of about 54,558 (298)
Molecular Oncology, EarlyView.The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
Liquid biopsy‐based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis
Molecular Oncology, EarlyView.This schematic outlines the workflow from biomarker identification to duplex MethyLight assay validation for epithelial ovarian cancer diagnosis using cfDNA‐based liquid biopsy. Initial screening of hypermethylated CpG candidates (cg02957270, cg10061138 cg00480298, COL2A1) was performed in tissue using ARMS‐PCR, COBRA, qPCR and image analysis. Selected
Deepa Bisht +3 more
wiley +1 more source
International Journal of Industrial Engineering and Production Research, 2016 Process capability indices (PCIs) can be used as an effective tool for measuring product quality and process performance. In classic quality control there are some limitations which prevent a deep and flexible analysis because of the crisp definition of ...
Rahebe Keshavarzi +1 more
doaj
Desirability to characterize process capability [PDF]
Over the past few years continuously new process capability indices have been developed, most of them with the aim to add some feature missed in former process capability indices.
Weihs, Claus, Jessenberger, J.
core
Loss-based process capability indices: a review [PDF]
, 2011 Process capability indices (PCIs) are appropriate tools to measure the inherent capability of a process, but most of them do not consider the losses of a process, while in today's competitive business environment, it is becoming more and more important ...
Tang Sai Hong +7 more
core +1 more source
Molecular Oncology, EarlyView.Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim +3 more
wiley +1 more source
IEEE Access, 2018 This paper proposes a control chart using repetitive sampling for monitoring process capability index having one-sided specification limit using an exact distribution.
Muhammad Aslam
doaj +1 more source
Molecular Oncology, EarlyView.BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi +11 more
wiley +1 more source
IEEE Access, 2016 This paper investigates the efficiency of Gini's mean difference (GMD) as a measure of variability in two commonly used process capability indices (PCIs), i.e., Cp and Cpk.
Muhammad Kashif +3 more
doaj +1 more source
The communion bridge to Six Sigma and Process capability indices
, 2010 [[abstract]]Six Sigma has already become an efficient improvement technique adopted by a great number of enterprises. Numbers of Sigma has become a tool of measuring process capability in some enterprises.
Chen, K. S.; Ouyang, L. Y. ; Hsu, C. H.
core